Insmed Incorporated
INSM
株式のランク
#1109
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
株価
$95.88
時価総額
$20.94B
変化（1日）
0.61%
変化（1年）
-42.90%
国
US
取引 Insmed Incorporated (INSM)
カテゴリー
Healthcare
Insmed Incorporated（INSM）の株式分割履歴
Insmed Incorporated株（シンボル：INSM）は合計で2回の株式分割を実施しました。
最新の株式分割はMar 03, 2011に行われました。
Jul 31, 2000より前に購入されたINSM株は、現在0.025INSM株に相当します。
最新の株式分割はMar 03, 2011に行われました。
Jul 31, 2000より前に購入されたINSM株は、現在0.025INSM株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 2011-03-03 | 1:10 | x0.1 | x0.025 |
| 2000-07-31 | 1:4 | x0.25 | x0.25 |
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
